November 17, 2026, 12pm-1pm ET

From the lab to the community: Familial Alzheimer’s disease in Jalisco, Mexico

Speakers: Dr. Angélica Zuno Reyes and Frida Rosales Leycegui

Autosomal dominant Alzheimer’s disease (ADAD) is a rare, inherited form of early- onset Alzheimer’s disease (AD) caused by nearly fully penetrant mutations, affecting families for generations. Because carriers of a causal mutation are born with a genetic alteration that virtually guarantees the onset of symptoms, often at a predictable age, ADAD offers a unique opportunity to study the disease before it manifests and throughout its stages, and to design preventive interventions for AD and related dementias. In Jalisco, Mexico, two large ADAD populations have been identified, carrying the PSEN1A431E (“Jalisco mutation”) or the APPV717I mutation.

This talk presents the work of a binational, multidisciplinary team at the Universidad de Guadalajara and the University of Southern California. Through an ongoing research protocol, the team has reconstructed historical pedigrees and conducted longitudinal functional, clinical, and cognitive assessments, as well as biosample collection, among other activities. Beyond the laboratory, we describe how community meetings and events, the development and implementation of genetic counseling programs, and social work and caregiving support have sustained long-term participant adherence, and how participants have become active partners in the research. Finally, we discuss future directions in neuroimaging, biomarkers, and clinical trials, and the role of community engagement in making ADAD research accessible and useful to the families it serves.

Please note that registration is required to attend. Click here to register.

December 15, 2026, 12pm-1pm ET

Genetic, pathologic and hormonal contributions to psychosis in Alzheimer’s disease

Speaker: Corinne Fischer

This presentation will examine putative mechanisms underlying psychosis in Alzheimer’s disease and how sex, APOE4 status and brain pathology may play a role. Specifically, we will examine how APOE4 status interacts with sex and pathology to determine psychotic phenotypes and how this knowledge may inform treatment. We will also examine the protective role of estrogen therapy in Alzheimer’s disease-related psychosis.

Please note that registration is required to attend. Click here to register.

Past webinars

What are you looking for?

  • SYNERGIC Trial: The first Canadian multidomain intervention trial to improve cognition in Mild Cognitive Impairment

    October 31, 2023

  • Results of ENGAGE trial and next steps

    October 3, 2023

  • New features and data querying workshop

    September 19, 2023

  • Food for thought: The role of dietary intake and nutrition risk in cognitive health among older adults

    September 5, 2023

  • Creative connections: The CCNA training program in phase II

    June 27, 2023

  • The impact of Canada’s pivotal work in dementia diagnosis and care in primary care settings – Will governments and specialist clinicians engage?

    June 13, 2023

  • Amyloid clearance by amyloidolytic activity

    May 30, 2023

  • Selective immunotherapies for Alzheimer’s disease and synucleinopathies

    April 25, 2023

  • An honest conversation on building meaningful engagement with diverse communities in dementia research

    March 23, 2023

  • Understanding stigma against dementia during COVID-19: Lived Experience and Social Media Research

    January 18, 2023

  • Cohesion, At-homeness, and Playfulness (CAP): A place-based model to prevent cognitive decline in the community

    November 30, 2022

  • Staging Alzheimer’s disease in vivo

    August 15, 2022

Illustration of elderly people on a park bench
CCNA - CCNV logo

Get the latest news

Keep up to date with the latest research developments at CCNA. Our “News” section provides information on studies, new developments and key findings in brain health research.